Revised outcome of unaudited Standalone and consolidated financial results for the Quarter ended 30-06-2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has filed a corrected PDF version of its Q1 FY26 results after reporting editing errors in the PDF originally uploaded on 14 August 2025; the XBRL version was already correct. On a consolidated basis, revenue from operations fell to ₹2,910.37 Lakhs from ₹3,152.78 Lakhs in Q1 FY25, a decline of about 7.7%. Total income dropped to ₹3,015.99 Lakhs and net profit after tax sharply declined to ₹15.65 Lakhs from ₹85.02 Lakhs, down roughly 81.6% year-on-year, with EPS at ₹0.03 versus ₹0.10. Operating profit before provisions also compressed to ₹20.87 Lakhs from ₹94.47 Lakhs. On a standalone basis, revenue declined to ₹668.57 Lakhs from ₹1,079.09 Lakhs, but net profit was largely flat at ₹12.77 Lakhs versus ₹12.72 Lakhs. Statutory auditor Venkatesh & Co issued a clean limited review report with no qualifications or emphasis of matter.
This is largely a procedural correction—the financial substance was already captured in the correct XBRL filing, so the stock impact should be minimal. However, the underlying consolidated results show meaningful revenue and profit weakness versus last year, which investors should factor into their assessment of the company's Q1 performance.